Screener
Biohaven
BHVNBiohaven is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies for immunology, neuroscience, and oncology.
Earnings
Next report
Nov 9, 2026 (in 2 months)Revenue estimate$70.0M
EPS estimate-$0.61
Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Biohaven is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies for immunology, neuroscience, and oncology. The company leverages proprietary drug development platforms, including extracellular protein degradation, to advance a diverse pipeline of treatments for high-unmet-need conditions such as epilepsy and metabolic disorders.
Competitive position
A late-stage clinical developer focused on high-value therapeutic areas following its spin-off from its former parent company.
GeographiesGlobal
Customer segmentsHealthcare providers, Patients
Business modelR&D intensive, IP licensing, Drug development
SuppliersContract manufacturing organizations, Clinical research organizations, Academic research institutions
CustomersHospitals, Specialty pharmacies, Wholesale distributors
CountryUnited States of America
Listed2022
Employees239.0
CEOVladimir Coric
SectorHealthcare
IndustryBiotechnology
Websitebiohavenpharma.com
FilingsSEC EDGAR
FAQ
- What is Biohaven's market cap?
- Biohaven (BHVN) has a market capitalization of $1.8B and trades on NYSE.
- Who are Biohaven's competitors?
- Biohaven's key competitors include Eli Lilly and Company, Passage Bio, Inc. Common Stock, Vyome Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Biohaven partner with?
- Biohaven's notable partners include Pfizer Inc..
- What subsidiaries does Biohaven have?
- Biohaven's subsidiaries include Biohaven Pharmaceuticals Inc..
- Where is Biohaven headquartered?
- Biohaven is headquartered in United States of America and employs approximately 239 people. It has been publicly traded since 2022.